Table 3.
Results of repeated variables over the follow-up study period in eyes with mature mCNV (n = 21).
| Variable | Baseline | 1 month | 6 months | 12 months | p value |
|---|---|---|---|---|---|
| BCVA (logMAR) | 0.60 ± 0.34 | 0.46 ± 0.31 | 0.36 ± 0.24a | 0.42 ± 0.26 | 0.046A |
| Ellipsoid zone disruption (n) | 19 (90.5%) | 13 (61.9%) | 1 (4.8%)b | 2 (9.5%)b | < 0.001Q |
| Subretinal hyperreflective exudation (n) | 19 (90.5%) | 13 (61.9%) | 1 (4.8%)b | 0 (0%)b | < 0.001Q |
| Intraretinal cysts (n) | 9 (42.9%) | 10 (47.6%) | 4 (19.0%) | 1 (4.8%)c | 0.001Q |
| Subretinal fluid (n) | 11 (52.4%) | 2 (9.5%)d | 0 (0%)b | 2 (9.5%)d | < 0.001Q |
| CNV area (mm2) | 1.01 ± 0.53 | 0.92 ± 0.50 | 0.83 ± 0.41 | 0.85 ± 0.41 | 0.618A |
| Subretinal fibrosis (n) | 0 (0%) | 0 (0%) | 9 (42.9%)e | 17 (81%)f | < 0.001Q |
Significant values are in bold.
AANOVA test; QCochran’s Q test; a0.046 (Tukey HSD vs baseline); b< 0.001(McNemar vs baseline); c0.009 (McNemar vs baseline); d0.012 (McNemar vs baseline); e0.027 (McNemar vs baseline); f0.002 (McNemar vs baseline).
BCVA Best-Corrected Visual Acuity, CNV Choroidal neovascularization, logMAR logarithm of the minimal angle of resolution, mm millimeter.